New York, Nov 30, 2020, SPA -- Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said according to Reuters. Moderna also reported that its vaccine's efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people. The filing sets Moderna's product up to be the second vaccine likely to receive U.S. emergency use authorization this year following a shot developed by Pfizer and BioNTech which had a 95% efficacy rate. "We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it," Moderna Chief Medical Officer Tal Zaks said. "We expect to be playing a major part in turning around this pandemic." Of the 196 people who contracted COVID-19 out of over 30,000 volunteers, 185 had received a placebo and 11 got the vaccine. Moderna reported 30 severe cases, all in the placebo group, which means the vaccine was 100% effective against severe cases. Moderna shares were up 6.7% at $138.58 in U.S. pre-market trade, a record high and a rise of more than 600% this year. --SPA 17:02 LOCAL TIME 14:02 GMT 0014 www.spa.gov.sa/w1459887